India’s Semaglutide battle: Zydus and Lupin to Co-market the blockbuster weight loss drug

The global landscape for weight-loss medications has shifted from a period of intense litigation to one of strategic “co-opetition.” Following the landmark settlement between Novo Nordisk and Hims & Hers over the compounding of Wegovy, a new chapter in this pharmaceutical saga is unfolding in the Indian market. On March 17, 2026, Indian pharma giants Zydus Lifesciences and Lupin announced a definitive agreement to co-market a generic version of the semaglutide injection in India. This move signals a transition from the legal defensive maneuvers seen in the West toward a high-volume, collaborative distribution model aimed at capturing the world’s fastest-growing healthcare consumer base.

The primary precedent for this shift occurred in the United States between Novo Nordisk and the telehealth giant Hims & Hers Health; chalking a crucial roadmap for how patent holders and secondary manufacturers might coexist. In that instance, the resolution of a high-profile lawsuit replaced courtroom conflict with a structured supply agreement, ensuring that high demand for Semaglutide could be met through diversified channels.

While the U.S. companies were shaking hands, the Delhi High Court was delivering a far more disruptive verdict that favors generic manufacturers. In a pivotal case involving Novo Nordisk and Dr. Reddy’s Laboratories, the court has consistently refused to grant an interim stay against the production of semaglutide by Indian pharmaceutical companies. On March 9, 2026, coincidentally the same day as the Hims & Hers settlement, a Division Bench of the Delhi High Court (Justices C. Hari Shankar and Om Prakash Shukla) upheld a previous ruling that denied Novo Nordisk an interim injunction. The court’s reasoning was two-fold. First, the court noted that Dr. Reddy’s and other Indian firms had raised a “prima facie credible challenge” to the validity of Novo Nordisk’s secondary patents. The bench observed that Semaglutide might be considered “obvious” from earlier disclosed chemical teachings, making the patent vulnerable to revocation under the Indian Patents Act. Second, with Novo Nordisk’s specific patent in India set to expire on March 20, 2026, the court questioned the utility of a last-minute stay. The bench pointedly asked why it should spend valuable judicial time on a patent with mere days left, opting instead to allow generic firms to prepare for a full-scale market entry.

The Zydus-Lupin partnership reflects a strong post-patent era strategy. With the expiry of exclusive manufacturing and selling rights of Novo Nordisk for Semaglutide after 20th March, Zydus and Lupin are free to engage the market with their version of Semaglutide products. By joining forces, these two domestic leaders are pooling their massive marketing and distribution networks to ensure that Semaglutide reaches both urban centers and Tier-II cities across India.

From an analytical perspective, this co-marketing deal is a direct response to the “patent cliff” and the subsequent race for accessibility. While Western markets have been defined by battles over intellectual property and the legality of compounded alternatives, the Indian market is prioritizing rapid scale. The partnership allows Zydus and Lupin to share the heavy lifting of medical education and physician outreach, which is essential for a drug that requires specific clinical oversight for obesity and type-2 diabetes management. This collaborative approach effectively lowers the barrier to entry for a life-changing medication that has historically been plagued by supply shortages and prohibitive pricing.

The economic implications of this “continuing saga” are profound. Just as the Hims & Hers deal stabilized the supply chain in the United States, the Zydus-Lupin alliance is expected to bring a level of price competitiveness to the Indian market that was previously absent. This is particularly relevant given India’s high prevalence of metabolic disorders. By leveraging domestic manufacturing capabilities, these companies are positioning India not just as a consumer of global biotech, but as a hub for affordable, high-quality generic versions of the world’s most sought-after drugs.

Ultimately, the shift from the litigation seen in early 2026 to the co-marketing agreements of mid-March suggests that the pharmaceutical industry has recognized a fundamental truth: the demand for semaglutide is too large for any single entity to satisfy. Whether through settlements that end lawsuits or partnerships that bridge distribution gaps, the narrative is moving away from exclusivity. As Zydus and Lupin begin their joint rollout, the “semaglutide saga” enters a phase of democratization, where the focus moves from protecting a patent to protecting public health on a global scale.